Peanut allergy research hits the headlines
admin | May 16, 2014
Peanut allergy can cause severe reactions and is the most common food-related cause of potentially fatal anaphylaxis, so when news broke of the publication in The Lancet of a hugely significant new therapy for peanut allergy there was wide coverage in the media, both in the UK and internationally.
In the phase two clinical trial at Addenbrooke's Hospital the majority of children given the treatment were able to tolerate eating at least five peanuts.
Using various news items from the week following the publication of the research, Media Studio worked with the Tust's PR & Communications Team to put together the whole story of the breaking news in a film that was shown to the Trust Board as a superb example of translational research at CUH. Media Studio then shot an interview with Principal Investigator Dr Andrew Clark to explain the role of the NIHR Clinical Research Facility (CRF), adding Dr Clark's sequence to the news story to make a new film for distribution among other CRFs nationally.
Pamela Sole, Study Information Manager for the CRF, said:
'This study is a perfect example of what the NIHR/Wellcome Trust Clinical Research Facility (CRF) at Addenbrooke's Hospital does and how it has supported this study from the start, when it was a pilot study, through the phase 2 study to becoming a new treatment for patients with peanut allergy. It is a great example of what CRFs are here to do.'
The original pilot study was funded by the Evelyn Trust and resulted in a substantial NIHR grant to carry out the three-year phase two clinical trials, with the additional support of the NIHR-funded Cambridge Biomedical Research Centre. The research was led by Addenbrooke's Consultants Dr Pamela Ewan and Dr Andrew Clark.
We are grateful to all the news agencies and broadcasters that gave their permission for us to use footage from their transmissions.